Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of XS004 (Dasatinib) vs Sprycel in healthy adults
NCT05439408Phase 1Completed
- Sponsor
- Xspray Pharma
- Start
- Jun 2021
- Primary completion
- Jun 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dasatinib in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Xspray Pharma. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve from Zero to Last Measurable Concentration and 1 more. Started Jun 2021; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05439408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05439408.